IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

Autor: Xavier Jaumont, Marc Humbert, Nikolaos G. Papadopoulos, Ioannis Kottakis, Oscar Palomares, Jean Bousquet, Simon Francis Thomsen, Pascal Pfister, Claus Bachert
Přispěvatelé: Hôpital Bicêtre, Hôpital Arnaud de Villeneuve [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Ghent University Hospital, National and Kapodistrian University of Athens (NKUA)
Rok vydání: 2019
Předmět:
Hypersensitivity
Immediate

Allergy
CHRONIC RHINOSINUSITIS
Omalizumab
Immunoglobulin E
FOOD ALLERGY
Allergic rhinitis
DOUBLE-BLIND
0302 clinical medicine
immune system diseases
Anti-Allergic Agents
Medicine and Health Sciences
ATOPIC-DERMATITIS
Immunology and Allergy
030212 general & internal medicine
[SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology
Conjunctivitis
Allergic

biology
Atopic dermatitis
3. Good health
Multimorbidities
RAPID ORAL DESENSITIZATION
[SDV.IMM]Life Sciences [q-bio]/Immunology
MAST-CELLS
Allergic bronchopulmonary aspergillosis
Food Hypersensitivity
medicine.drug
CASE SERIES
Dermatitis
Atopic

03 medical and health sciences
Nasal Polyps
Rhinoconjunctivitis
Food allergy
medicine
Humans
Vernal keratoconjunctivitis
Sinusitis
Asthma
BRONCHOPULMONARY ASPERGILLOSIS
business.industry
Aspergillosis
Allergic Bronchopulmonary

Multimorbidity
medicine.disease
Rhinitis
Allergic

Chronic rhinosinusitis with nasal polyps
respiratory tract diseases
Treatment
ANTI-IGE
030228 respiratory system
VERNAL KERATOCONJUNCTIVITIS
Food allergies
Chronic Disease
Immunology
biology.protein
business
Zdroj: JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
Journal of Allergy and Clinical Immunology: In Practice
Journal of Allergy and Clinical Immunology: In Practice, Elsevier, 2019, 7 (5), pp.1418-1429. ⟨10.1016/j.jaip.2019.02.030⟩
Humbert, M, Bousquet, J, Bachert, C, Palomares, O, Pfister, P, Kottakis, I, Jaumont, X, Thomsen, S F & Papadopoulos, N G 2019, ' IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy ', The Journal of Allergy and Clinical Immunology: In Practice, vol. 7, no. 5, pp. 1418-1429 . https://doi.org/10.1016/j.jaip.2019.02.030
ISSN: 2213-2198
Popis: Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influence asthma control, its severity, and patients' response to treatment, and contribute to the overall socioeconomic burden of the disease. Immunoglobulin E (IgE) is known to play a central role in the pathogenesis of various allergic diseases, including asthma. Thus, IgE-mediated immunologic pathways present an attractive target for intervention in asthma and multimorbidities. In this review, we discuss the most frequently reported IgE-mediated multimorbidities in allergic asthma, including allergic rhinitis, rhinoconjunctivitis, atopic dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis. Omalizumab is a recombinant humanized monoclonal antibody against IgE and has been in use to treat allergic asthma for more than a decade. We comprehensively review the clinical evidence for omalizumab in the treatment of the aforementioned multimorbidities in allergic asthma. (C) 2018 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
Databáze: OpenAIRE